Cytokinetics, Incorporated (CYTK) Stock Overview
Explore Cytokinetics, Incorporated’s financial performance, market position, analyst ratings, and future outlook.
Cytokinetics, Incorporated (CYTK)
Key Financials
Key Financials
Market Cap
8.9B
P/E Ratio
-10.52
EPS (TTM)
$-6.85
ROE
1.40%
CYTK Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Cytokinetics, Incorporated (CYTK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 45.65, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $67.86.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -10.52 and a market capitalization of 8.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.